Applied Clinical Trials
Medidata
In the ongoing search for resource and timeline efficiencies, Clinical R&D organizations have paid particular attention over the years to data standards and reuse. This has included the standardization and reuse of case report forms (CRFs) and more recently EDC-based CRFs (eCRFs). Two important measures are expected to be improved through increasing the reuse of eCRFs:
The graph illustrates that clinical R&D organizations have indeed realized dramatically higher levels of eCRF reuse over the past five years—from about 10% in 2007 to just under 60% in 2011. The data was compiled from the Medidata Insights database comprising close to 1,800 studies from 52 contributing sponsors. As evidenced in this data, and bolstered by first-hand feedback from customer-facing teams, there is a broad industry trend toward greater reuse.
However, somewhat unexpected is the apparent lack of corresponding progress in reduced eCRF design periods. The graph shows that the overall trend is somewhat lower—from 15.1 weeks in 2007 to 13.9 weeks in 2011. However, the reduction is not nearly as demonstrable as the increase in eCRF reuse. There are a number of possible explanations for this, including, but not limited to the following:
Medidata is interested to hear your take on these observed trends. Have you seen increased eCRF reuse? Has it corresponded to shorter design periods? Have you seen other benefits including reduced effort and resources required? Continue to stay tuned to this blog as we'll be delving further into the Insights metric data throughout 2012.
—Medidata Solutions, www.mdsol.com
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.